What is the 13F Pro Quality Score for MDGL?

13F Pro ranks MADRIGAL PHARMACEUTICALS, INC. (MDGL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MDGL's current score at https://13fpro.ai/research/MDGL (free sign-up required for the full ranking).

Which hedge funds own the most MDGL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MDGL include BAKER BROS. ADVISORS, JANUS HENDERSON GROUP PLC, RTW INVESTMENTS,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MDGL as soon as new 13F filings post.

Where does 13F Pro source MDGL data?

All MADRIGAL PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. MADRIGAL PHARMACEUTICALS, INC. files with the SEC under CIK 1157601. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MDGL in?

MADRIGAL PHARMACEUTICALS, INC. (MDGL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MDGL research updated on 13F Pro?

MDGL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MADRIGAL PHARMACEUTICALS, INC.(MDGL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1157601 MDGL stock profile & AI dashboard →

13F Pro Quality Score

25.4/100

Rank #2,544 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

13.6/100

Balance Sheet

9.0/100

Earnings Quality

30.0/100

Free Cash Flow

12.9/100

Institutional Flow

88.7/100

Revenue Scale

48.4/100

Dilution Risk

4.5/100

MDGL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MADRIGAL PHARMACEUTICALS, INC. (MDGL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDGL at 25.4/100 on a 32-signal composite quality model, placing it at rank #2,544 of 2,879 stocks — the bottom half of the AI-ranked universe. MDGL scores in the top quartile across institutional flow (88.7). Areas of concern include balance sheet strength (9.0) and free cash flow (12.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MADRIGAL PHARMACEUTICALS, INC. reports quarterly revenue of $311.3M, net income of $-94.4M, an operating margin of -29.8%. Top institutional holders of MDGL by reported 13-F value include BAKER BROS. ADVISORS, JANUS HENDERSON GROUP PLC, RTW INVESTMENTS,, based on the most recent SEC filings. MDGL trades on the Nasdaq exchange and files with the SEC under CIK 1157601. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MADRIGAL PHARMACEUTICALS, INC. directly from SEC EDGAR. MADRIGAL PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 8 and 37 since 2025, currently 25.4 — an improving long-term trajectory across 40 quarterly and live scoring snapshots.

✦

Fun facts about MADRIGAL PHARMACEUTICALS, INC.

Quirks, history, and lore behind MDGL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
For years it burned cash with no approved products, then its first commercial launch sent the stock up hundreds of percent in a single year — from obscurity to Wall Street darling overnight.
3
The History
Founded in the early 2000s, it spent nearly two decades quietly running clinical trials before finally cracking one of liver disease's most stubborn problems.
4
The Secret
Its entire bet is on thyroid hormone receptor beta agonism — a precise mechanism designed to target the liver without the heart side effects that sank earlier drugs in the class.
5
The Lore
Its lead drug, resmetirom, became the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) — a disease affecting tens of millions Americans with virtually no prior options.
6
The Giveaway
One drug, one disease, one historic approval: Rezdiffra for MASH — launched in 2024 by a small Pennsylvania pharma that finally gave fatty liver disease its first-ever medicine.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$311.3M

Net Income

Q1 2026

$-94.4M

Free Cash Flow

Q1 2026

$-171.3M

Operating Margin

Q1 2026

-29.8%

D/E Ratio

Q1 2026

0.63

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$180.1MFY 2024

FY14 —FY18 $0.00FY23 $0.00FY24 $180.1M

Net Income

-24.7% YoY

$-465.9MFY 2024

FY14 —FY18 $-32.8MFY23 $-373.6MFY24 $-465.9M

Operating Income

-30.8% YoY

$-497.9MFY 2024

FY14 $-84.0MFY18 $-40.7MFY23 $-380.5MFY24 $-497.9M

EPS (Diluted)

+13.4% YoY

$-17.31FY 2024

FY14 —FY18 —FY23 $-19.99FY24 $-17.31

Total Assets

+62.7% YoY

$1.04BFY 2024

FY14 $100.7MFY18 $485.4MFY23 $640.5MFY24 $1.04B

Total Debt

+1.8% YoY

$117.6MFY 2024

FY14 —FY18 —FY23 $115.5MFY24 $117.6M

Op. Cash Flow

-40.5% YoY

$-455.6MFY 2024

FY14 —FY18 $-25.5MFY23 $-324.2MFY24 $-455.6M

Metric	FY 2024	FY 2023	FY 2018	FY 2014	FY 2013	FY 2011
Revenue	$180.1M	$0.00	$0.00	—	—	—
Net Income	$-465.9M -24.7%	$-373.6M -1038.7%	$-32.8M	—	—	—
Operating Income	$-497.9M -30.8%	$-380.5M -835.3%	$-40.7M +51.5%	$-84.0M +4.1%	$-87.6M -92.7%	$-45.4M
EPS (Diluted)	$-17.31 +13.4%	$-19.99	—	—	—	$-1.00
Total Assets	$1.04B +62.7%	$640.5M +32.0%	$485.4M +382.2%	$100.7M +5.7%	$95.2M +124.9%	$42.3M
Total Debt	$117.6M +1.8%	$115.5M	—	—	—	—
Operating Cash Flow	$-455.6M -40.5%	$-324.2M -1171.1%	$-25.5M	—	—	—

AI Insight: MDGL Financial Trends

Revenue surged from $15M to $311M over eight quarters, but operating losses persist and equity declined from $857M to $543M.

• Revenue accelerated dramatically from $15M in Q2 2024 to $311M in Q1 2026, representing 20x growth.

• Operating losses narrowed from $163M in Q2 2024 to $93M in Q1 2026 despite revenue scale-up.

• Total debt increased from $117M to $340M starting in Q3 2025, nearly tripling leverage.

• Equity declined steadily from $857M in Q2 2024 to $543M in Q1 2026, reflecting cumulative losses.

⚠ Operating cash flow turned sharply negative to $167M in Q1 2026 after positive $80M in Q3 2025.

⚠ Revenue growth decelerated to $311M in Q1 2026 from $321M peak in Q4 2025, first quarterly decline.

AI Insight: MDGL Ratio Trends

Operating losses persist with negative margins ranging from -18% to -187% across quarters, though Q4 2025 showed best performance at -18.6%.

• Operating margin improved significantly from -187.1% in Q3 2024 to -18.6% in Q4 2025.

• Debt-to-equity ratio increased from 0.14 in Q2 2024 to 0.63 in Q1 2026.

• Return on invested capital remained deeply negative, ranging from -66.8% to -23.2% across all quarters.

⚠ Operating margin deteriorated from -18.6% in Q4 2025 to -29.8% in Q1 2026, reversing improvement trend.

⚠ Leverage spike in Q3 2025 with debt-to-equity jumping from 0.17 to 0.54 in one quarter.

Get alerted when MDGL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MADRIGAL PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MDGL

BAKER BROS. ADVISORS LP
$1.1B2,141,701 sh
JANUS HENDERSON GROUP PLC
$1.1B2,018,647 sh
RTW INVESTMENTS, LP
$1.0B1,993,687 sh
Avoro Capital Advisors LLC
$951.8M1,818,181 sh
BlackRock, Inc.
$816.6M1,559,965 sh
PAULSON & CO. INC.
$728.8M1,392,188 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$440.3M841,145 sh
VANGUARD CAPITAL MANAGEMENT LLC
$433.0M827,144 sh
WELLINGTON MANAGEMENT GROUP LLP
$363.8M694,958 sh
STATE STREET CORP
$319.1M609,525 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$1.1B	2,141,701
JANUS HENDERSON GROUP PLC	$1.1B	2,018,647
RTW INVESTMENTS, LP	$1.0B	1,993,687
Avoro Capital Advisors LLC	$951.8M	1,818,181
BlackRock, Inc.	$816.6M	1,559,965
PAULSON & CO. INC.	$728.8M	1,392,188
VANGUARD PORTFOLIO MANAGEMENT LLC	$440.3M	841,145
VANGUARD CAPITAL MANAGEMENT LLC	$433.0M	827,144
WELLINGTON MANAGEMENT GROUP LLP	$363.8M	694,958
STATE STREET CORP	$319.1M	609,525

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MDGL on your watchlist

Track score changes the day MADRIGAL PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MDGL a good stock to buy?

13F Pro's AI-powered analysis of MADRIGAL PHARMACEUTICALS, INC. (MDGL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDGL are available on the MDGL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MDGL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDGL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MADRIGAL PHARMACEUTICALS, INC.'s investment landscape.